Our laboratory focuses on biomarker discovery in cutaneous lymphoma and novel treatment strategies based on immunobiological aspects of the tumor biology.
Biomarker discovery is a rapidly developing field of modern medicine and in particular, of great interest in the early detection of cancer. Luminex technology and targeted proteomics are now a well-established tool for quantitative proteomics and have been used successfully in the discovery of biomarkers for various cancers. We have a considerable interest in utilizing these technologies to discover new biomarkers for cutaneous T-cell lymphomas (CTCL).
Recent studies indicate that CD47-SIRPα signaling system plays important roles in tumor immune surveillance through regulation of the phagocytic activity of macrophages. High expression of CD47 on tumor cells masks them from phagocytosis and elimination. We evaluate if the CD47-SIRPα blockade can be an efficient modality for treatment of patients with Sézary syndrome.